Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus
- Conditions
- The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mgPlus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks inSubjects With Type 2 Diabetes Mellitus.
- Interventions
- Drug: Metformin/Acarbose
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2010-11-22
- Lead Sponsor
- Lotus Pharmaceutical
- Target Recruit Count
- 220
- Registration Number
- NCT01245166
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria
- Conditions
- Chronic Idiopathic UrticariaUrticaria
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2006-06-30
- Lead Sponsor
- Lotus Pharmaceutical
- Target Recruit Count
- 60
- Registration Number
- NCT00346606
- Locations
- 🇨🇳
Department of Dermatology National Taiwan University Hospital, Taipei, Taiwan
Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
- Conditions
- Migraine With AuraMigraine Without Aura
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2007-09-10
- Lead Sponsor
- Lotus Pharmaceutical
- Target Recruit Count
- 74
- Registration Number
- NCT00334178
- Locations
- 🇨🇳
Changhua Christian Hospital, Changhua, Taiwan
🇨🇳Chung-Ho Memorial Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
🇨🇳Chang-Gung Memorial Hospital, LinKou, Taiwan
News
LENZ Therapeutics and Lotus Pharmaceutical Forge $125 Million Deal for Presbyopia Treatment in Southeast Asia
LENZ Therapeutics has partnered with Lotus Pharmaceutical in a deal worth up to $125 million plus double-digit royalties to commercialize LNZ100, an aceclidine-based eye drop for presbyopia, in Korea and Southeast Asia.
Formycon Expands Global Reach for Eylea Biosimilar Through Strategic Partnerships with Teva and Lotus Pharmaceutical
Teva Pharmaceuticals secured semi-exclusive commercialization rights for FYB203 (AHZANTIVE), Formycon's aflibercept biosimilar, across major European markets and Israel following FDA approval in June 2024.